GlassScriptPhysician profile
Ling Min Gao
NPI 1215947429
$24,961.86
in general payments reported to CMS, 2019-2025
38 companies · $2,738 in 2025
The $2,738 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,989 · 2020: $2,091 · 2021: $3,961 · 2022: $3,257 · 2023: $3,306 · 2024: $3,620 · 2025: $2,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,641 · Education: $23.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,640.76 |
| Education | $23.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,657.22 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $2,823.77 | 2019-2025 | |
| Gilead Sciences, INC. | $2,736.83 | 2019-2025 | |
| Glaxosmithkline, LLC. | $2,205.94 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Janssen Pharmaceuticals, INC | $1,579.02 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,238.28 | 2019-2025 | Jardiance, Synjardy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,125.71 | 2023-2025 | Caplyta |
| Amarin Pharma, INC. | $844.87 | 2019-2023 | |
| Novo Nordisk INC | $815.48 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $730.54 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $724.40 | 2020-2024 | Linzess |
| Merck Sharp & Dohme LLC | $699.84 | 2019-2023 | Steglatro |
| Allergan, INC. | $689.21 | 2019-2020 | |
| Amgen INC. | $616.99 | 2023-2025 | Repatha, Otezla, Otezla |
| Phathom Pharmaceuticals, INC. | $601.99 | 2024-2025 | Voquezna |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ling Min Gao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.